Biocon chief Kiran Mazumdar-Shaw denies 'Pandora Papers' charges
The 68-year-old Biocon chairperson retorted that information related to overseas entities were disclosed to regulatory agencies, and Kunal Kashyap's role is devoid of any legal authority.
VIDEO - Future is bio-pharma: Kiran Mazumdar-Shaw
Biocon's executive chairperson Dr Kiran Mazumdar Shaw, calls for a PLI scheme specially focused on incentivising biopharma investment.
VIDEO - Shot in the foot with pharma price control: Shaw
The executive chairperson of Biocon exhorts the government to revisit pharma price controls from a global perspective, in order to incentivise local manufacturing in the industry.
Covid-19 is an endemic, not pandemic: Mazumdar-Shaw
Kiran Mazumdar-Shaw, the Biocon chief, feels hospitalisation and not infection count matters in the fight against Coronavirus.
Mix and match vaccines, says Kiran Mazumdar-Shaw
In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.
Syngene’s winning formula
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
Woman power: Against all odds
For the International Women’s Day, we celebrate the 50 women who featured in our Most Powerful Women (MPW) in Business list for the year 2020. Here’s the editor’s letter from that issue.
Budget 2021: Research, innovation get a boost
The Union Budget 2021 understands that for India to become the third-largest economy in the world, scientific research and innovation requires a policy boost.
Biocon’s biosimilar biz tops $4 bn in valuation
Abu Dhabi-based sovereign wealth fund ADQ has picked up 1.80% stake in Biocon Biologics for $75 million; The company already raised $255 million from global marquee investors last year.
‘Restart economy sooner than later’
India is likely to recover faster than the rest of the world from the economic turmoil caused by Covid-19, with new opportunities presenting themselves, says Biocon chairperson.